CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
GSK1265744 30mg +2 moredrug
Likely dose
GSK1265744 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00920426
NCT00920426Phase 2Completed
CompareCT.gov

A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)

ViiV Healthcare·interventional·Posted Jun 15, 2009·Updated Dec 6, 2017

In Brief

A Phase 2 clinical trial evaluating GSK1265744 30mg, Placebo, and 1 other intervention for Infection, Human Immunodeficiency Virus. Completed, enrolled 9 participants across 4 sites.

Detailed Summary

The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood. It will also look at how people react to and how a human body uses GSK1265744. This study will compare the effects of GSK1265744 and placebo. The study will consist of 1 or 2 parts to look at doses of GSK1265744. About 8 people will take part in Part 1 of the study receiving dose A. If additional dosing information is needed after Part 1, about 6 people will take part in Part 2 of the study receiving dose B.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection, Human Immunodeficiency Virus
CountriesUnited States
CollaboratorsShionogi, GlaxoSmithKline

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 15, 2009
Enrollment StartJun 9, 2009
Primary CompletionAug 13, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.0 years ago

Interventions

GSK1265744 30mgdrug

GSK1265744 30 mg

Placebodrug

Placebo to match GSK1265744

GSK1265744 5mgdrug

GSK1265744 5mg